- Japan
- Market Indicator
- Price Momentum Indicators
- Richard Russell
- Silver
- Speed Resistance Lines
- U.S. Dividend Watch List
Category Archives: SLV
Silver Update: March 2018
On May 5, 2011, when the iShares Silver Trust (SLV) was trading at $33.72, we said the following:
“…we’d like to see the price decline to the dashed blue line at $15.41 or below.”
On March 12, 2017, we said:
“From what we can tell, there are only two remaining downside targets. The first is the January 2016 low at $13.74 or –19.31% from the March 10, 2017 closing price. The final low is at $9.02 or –47.03% from the March 10, 2017 close.”
The closest that the price of silver has come to $13.74 is the July 7, 2017 low of $15.34. Below is the revised update on the price of silver and our expectations going forward.
Silver: December 2017
Below is a comparison chart showing the price of silver since 2012 and our view on the direction of the “poor man’s gold.”
Silver Update
On May 5, 2011, when the iShares Silver Trust (SLV) was trading at $33.72, we said the following:
“…we’d like to see the price decline to the dashed blue line at $15.41 or below.”
Silver: Downside Targets Met
As early as May 5, 2011, when silver was trading at $35 an ounce, we’ve maintained the view that the prospect of silver, in the form of the exchange traded fund iShares Silver Trust (SLV), falling below $20 was well within the realm of possibility (article here). At the time, we said the following: Continue reading
Posted in Charles H. Dow, Dow Theory, Edson Gould, iShares Silver Trust, Silver, SLV, speed resistance line
Tagged members
Gold Stocks Near New Low
This is the list of gold related equities that we track within 10% of the one year low. We strongly recommend that you do your own research on these companies and assume that the downside risk is half of the current price, at minimum.
Precious Metals Follow-Up
Silver
On February 11, 2012, we wrote a piece on Silver and SLV titled “Correction of Errors on iShares Silver Trust (SLV) Interpretation” (found here). In that article, we said the following:
“The current indications suggest that SLV will fall as [low as] the $22.14 support level. Because silver easily fell to the third support level in the period from 2001 to 2008 (within the context of a precious metal bull market), we expect that the $21.02 is a realistic worst case scenario to watch for. We will consider buying silver and related derivatives at $22.25 and below.
“We view the most recent rise from the December 2011 low as running out of steam.Therefore, the rising resistance level established at $28.70 appears to be firmly in place…for now.”
As seen in the chart below, Silver has declined to the rising support level of $21.02 in many instances but broke through to the downside on February 18, 2013.
From a technical standpoint, the next downside target for silver may be to the $20 level if the current levels don’t hold. However, under typical circumstances, any point below the $21.02 level is considered undervalued. While it is possible that Silver could fall further we don’t play the short side since we’re in the position to accumulate good values. Values at this point trump the guesswork of when to enter and exit the short. We believe that anyone interested in the upside potential to silver should thoughtfully accept the potential loss of –50% or more and purchase in two stages, once at a predetermine price at or below the current level and a second time at or below the first purchase.
Agnico-Eagle Mines (AEM)
On April 6, 2012, we recommended the consideration of Agnico-Eagle Mines (AEM) (found here). On September 25, 2012, we recommended selling of AEM (found here). While we got a lot of heat from readers of the SELL recommendation, from the less than brilliant to the reasonably rational, our work has proven that precious metal bull markets are vicious and should not be taken lightly.
After our recommendation of AEM on April 6, 2012, the stock rose nearly +40%. When we gave the sell recommendation of AEM on September 25, 2012, the stock increased an additional +11%. However, as of April 12, 2013, AEM is down –27% from our sell recommendation and down –37% from the November 2012 high at $57.33.
Never under-estimate the power of a gold bull market. We hope that our work on this topic has been instructive.
Correction of Errors on iShares Silver Trust (SLV) Interpretation
-
$15.33
-
$12.51 (50%principle)
-
$9.68
-
$28.70 (50%principle)
-
$22.14
-
$21.02
Posted in Dow Theory, Error, gold, iShares Silver Trust, SLV
iShares Silver Trust (SLV) Update
“…we should see SLV tread water for a brief period of time before falling back to the prior low which began with the current run back in November 2008. Dow Theory suggests that a reasonable buying opportunity would exist at [or] below line B (blue line B).”
-
iShares Silver Trust (SLV) Debrief, May 5, 2011
iShares Silver Trust (SLV) Debrief
Bear market or not, some observations are worth considering. First, in the chart below, the overall pattern of the price decline in (SLV) for the Dow Theory indication numbered 1 (in green) is very similar to the current decline represented with the Dow Theory indication numbered 2 (in blue). Since Dow Theory works on a relative basis, once initiated at a major low, the signals provided are not confused through the distortions of large or small numbers. Headlines about SLV having declines of historic proportions are grossly exaggerated if there is no comparison on a percentage basis and compared to prior declines.
Second, at the beginning of each run at point 1 and 2, the price of SLV bounced off of the middle line B (also known as the 2/3 support line) before going parabolic.
Finally, the decline from each peak was rapid and vicious. One-third of the prior rise was wiped out in a matter of days after the peak.
Posted in Dow Theory, Edson Gould, gold, iShares Silver Trust, Silver, SLV, XAU
Sundry Items
-
Biogen Idec (BIIB) and Teva Pharmaceutical (TEVA) are doing a dance as both are members of the Nasdaq 100 index. As one stock is at a new high the other is reaching a new low. The two-step that is being done by the stocks is quite amazing. Back in October 30, 2009, we pointed out that the concentration of biotech stocks at a new low meant that they were possible takeover candidates. From that list in 2009, GENZ and CEPH were actually tendered buyout offers. 3 of the remaining 5 biotechs have had gains of 40% or more since then. The remaining two stocks, Amgen and Gilead Sciences, are essentially at break even. BIIB has been the leader in terms of price appreciation with a gain of over 100% since October 30, 2009. At that time TEVA was near a new 52-week high. However, BIIB’s recent success is actually impacting the performance of TEVA since both companies are involved in the development in MS drugs. TEVA is now on our new low list for the Nasdaq 100 and should be consider as a top acquisition candidate for your portfolio. Anyone who bought BIIB based on our watch list from October 2009 should now consider securing a large portion of the gains and possibly funding the purchase of TEVA with the proceeds.
-
Our September 5, 2009 article titled “Silver Should be the Focus” recommended that anyone interested in investing in gold should instead put there investment funds towards silver. The chart below reflecting the silver (SLV) and the gold (GLD) ETF demonstrates the accuracy of our recommendation and highlights what we believe is likely to come. Those interested in determining an entry point should reference our latest article on April 14, 2011 highlighting the downside targets for precious metal stocks based on the Philadelphia Gold and Silver Stock Index (XAU).
-
The results are in and our article titled “A Comparison Between Dividend Strategies” has demonstrated, so far, that the New Low approach has returned 19.52% while the list of stocks we compared ourselves to has returned only 1.39%. We believe that, although the two list have similar companies, the quality and timing has made the difference in performance. As a note, we only made the comparison because the author of the other list indicated that it was for the purpose of trading. In our view, stocks that can be considered for trading are worth comparing since we only aim for 1-year performance.





